Technology
Health
Biotechnology

Matinas BioPharma

$1.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.80%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MTNB and other stocks, options, ETFs, and crypto commission-free!

About

Matinas BioPharma Holdings, Inc., also called Matinas BioPharma, is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Read More Its lead anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.

Employees
15
Headquarters
Bedminster, New Jersey
Founded
2013
Market Cap
122.12M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.23M
High Today
$1.31
Low Today
$1.20
Open Price
$1.31
Volume
394.46K
52 Week High
$1.50
52 Week Low
$0.3237

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2017 IPO
US

News

Associated PressMar 15

Matinas BioPharma Announces Pricing of Public Offering of Common Stock

BEDMINSTER, N.J.--(BUSINESS WIRE)--Mar 15, 2019--Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Mat...

485
MarketBeatMar 2

Stock Price, News, & Analysis for Matinas BioPharma

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioa...

201
Markets InsiderFeb 25

Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer

BEDMINSTER, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer. Dr. Ferguson is a well-recognized, industry leading academic and clinical expert with over 25 years of experience in the cardiovascular space. He joins the Matinas BioPharma mana...

615

Earnings

-$0.05
-$0.04
-$0.04
-$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.03 per share
Actual
Expected Today, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.